Point72 Hong Kong LTD Protagonist Therapeutics, Inc Transaction History

Point72 Hong Kong LTD

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 15, 2022	SELL	$7.06 - $25.52 $40,270 - $145,566	-5,704 Closed	0 $0
Q1 2022 May 16, 2022	BUY	$23.34 - $36.08 $133,131 - $205,800	5,704 New	5,704 $135,000
Q1 2021 May 17, 2021	SELL	$19.02 - $31.15 $36,993 - $60,586	-1,945 Closed	0 $0
Q4 2020 Feb 16, 2021	BUY	$18.49 - $25.13 $35,963 - $48,877	1,945 New	1,945 $39,000
Q4 2019 Feb 14, 2020	SELL	$4.69 - $13.45 $173 - $497	-37 Closed	0 $0
Q3 2019 Nov 14, 2019	BUY	$9.41 - $16.56 $348 - $612	37 New	37 $0
Q2 2018 Aug 14, 2018	SELL	$5.99 - $9.1 $1,431 - $2,174	-239 Closed	0 $0
Q1 2018 May 15, 2018	BUY	$8.46 - $23.08 $1,556 - $4,246	184 Added 334.55%	239 $2,000
Q4 2017 Feb 14, 2018	BUY	$14.47 - $20.8 $795 - $1,144	55	55 $1,000

212

59.1M

19K

107K

Ticker PTGX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 49,084,100
Market Cap $2.25B
Description
Protagonist Therapeutics, Inc., a biopharmaceutical company, discovers and develops peptide-based therapeutic drugs to address hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing rusfertide (PTG-300), an injectable hepcidin mimetic that is in Phase II clinical trials for the treatment of patients with...

Get notified when there are updates to the investment portfolio of Point72 Hong Kong LTD, based on Form 13F filings with the SEC.

Stay updated on Point72 Hong Kong LTD with notifications on news.